The Healing Power of Marijuana Has Barely Been Tapped

By Allan Badiner | Alternet

Medical marijuana is now legal in 18 states, but it's clear we've discovered a fraction of its potential for health.

 

There are now legal medical cannabis programs in 18 states plus Washington, DC, with pot fully legal for adults in two other states. Ironically, however, the actual healing power of the plant has barely been tapped. Smoking marijuana with THC (tetrahydrocannabinol), or better, vaporizing it (using a device to bake the plant material and inhale the active ingredients), has an indisputably palliative effect and can be medically useful for pain relief, calming and appetite stimulation. It already has confirmed benefits against glaucoma, epilepsy and other specific diseases and disorders. It also gets people high. THC triggers cannabinoid receptors in the brain and this produces the sensation of being stoned. These receptors are found in the parts of the brain linked to pleasure, memory, concentration, and time perception.

But, based mostly on research overseas there is an increasing consensus that the medicinal benefits of psychoactive THC pale in comparison to the non-psychoactive cannabidiol (CBD) from the leaves of the same plant--raw and unheated. Depending on the strain, some plants are high in CBD but also contain a lesser amount of THC which is said to enhance the healing potentiality. CBD does not make people feel “stoned” and actually counters some of the effects of THC (for example, suppressing the appetite vs. stimulating it). CBD is beginning to be recognized by researchers at mainstream medical institutions around the world as a potentially very powerful weapon against cancer.  

 

Researchers Sean D. McAllister and Pierre Desprez, who conducted studies of CBD's effect on cancer cells for California Pacific Medical Center, suggest that these non-psychoactive compounds from the cannabis plant might, in short order, render chemotherapy and radiation distant second and third options for cancer patients. Based on a more recent study, McAllister and Desprez feel that CBD's "could stop breast cancer from spreading."

 

Dr. Donald Abrams, a cancer specialist and professor of integrative medicine at UCSF, conducted early trials involving THC medical cannabis, and now he is excited about the powerful impacts of CBD on cancer cells. The National Cancer Institute was busy researching this in the 1970s, Abrams explains, but restrictions on the use of cannabis for research in the United States resulted in most of the research on this subject disappearing in the U.S., and being picked up in other countries, such as Israel, Spain and Italy. He says existing studies point to a remarkable ability of CBD to arrest cancer cell division, cell migration, metastasis, and invasiveness. 

 

Other studies point to CBD as having great promise as a defense against Alzheimer’s disease. In a 2006 study published in Molecular Pharmaceutics, a team of University of Connecticut researchers reported that cannabis “could be considerably better at suppressing the abnormal clumping of malformed proteins that is a hallmark of Alzheimer’s disease than any currently approved prescription.” The research team predicted that cannabinoid-based medications "will be the new breakout medicine treatments of the near future.” 

 

Medical cannabis has a long history of use, starting in India, and then in China and the Middle East some 6,000 years ago. It came to the West in the 1800s, where it was listed in the U.S. Pharmacopeia until the 1930s. Used for over 100 ailments, cannabis was a favorite of our grandparents for cough remedies, analgesics, and tonics and was available over the counter at every local drugstore as well as companies such as Sears, Roebuck and Co. Banned in 1937 via the Marijuana Tax Act as part of a politically and racially driven prohibition craze, it was gradually removed from the pharmacopeia and research was discouraged and later prohibited via drug scheduling. The FBI linked the herb with insanity and claimed a direct correlation between cannabis and violence, and even death, especially when used by people of color.

Currently, science increasingly recognizes the role that cannabinoids play in almost every major life function in the human body. It wasn't until 1990 that endocannabinoids, produced by the human body, were discovered to act as a bio-regulatory mechanism for most human life processes and have receptors sites throughout the human body. CB2 receptors are found almost exclusively in the immune system, with the greatest density in the spleen. These CB2 receptors appear to be responsible for the anti-inflammatory and other newly recognized and very significant therapeutic effects of cannabis. 

 

Cannabis medicine has distinct advantages. CBD, as well as THC, can be given in massive doses with no side effects. In fact, it has performed very effectively as an anti-psychotic when given in high doses. CBD selectively targets and destroys tumor cells while leaving normal healthy cells unmolested. On the other hand, chemotherapy and radiation are highly toxic and indiscriminately injure healthy cells in the brain and the body. Industrial hemp is often high in healing CBD and very low in THC. Hemp CBD is a waste product -- it's thrown out by the ton every year when it could easily be harvested for tumor shrinking.  

 

Medical cannabis farm Tikun Olam in Israel has been developing a strain of cannabis that is high in CBD (15.8%) but very low in THC (1%). This new strain is called Avidekel and seems to have the highest CBD to THC ratio of any other variant strain. Zack Klein of Tikun Olam told Reuters: “Sometimes the high is not always what is needed. Sometimes it is an unwanted side effect. For some of the people it’s not even pleasant.”

 

The THC industry and its users worry that once CBD medicine grows in popularity, the medical badge might be torn from the sticky buds that makes being "stoned" possible. Aside from THC's significant medical benefits, surely its ability to make people feel happier and less stressed should not be considered without therapeutic value. More likely, all options will thrive, and 1,000 cannabis flowers will blossom: Indica, Sativa, CBD + THC, CBD Only, etc.

 

Meanwhile, it's useful to note that since 2003, the U.S. federal government has held a "medical patent" for the marketing of cannabinoids as antioxidants or neuroprotective agents. The patent states that cannabinoids are "useful in the treatment and prophylaxis of wide variety of oxidation associated diseases such as inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia."

 

However, stoners may have it all wrong, medically speaking. It is unlikely a person can get a sufficient level of cannabidiol (pronounced kan-nəbə-dī'-ˌȯl) from smoking the raw plant to impact diseases like cancer in a curative manner, says Desprez. The marijuana plant offers many uses, but it may come as a surprise to most users that you have to choose early in a plant's life if you want it to make you high or to heal you. Research suggests that cannabis is most beneficial when the whole spectrum of cannabinoids are represented, including some THC. It is the ratio of cannabinoids in a specific strain of cannabis that most determines its therapeutic potential. Juicing the cannabis leaves raw, along with some carrots or other green veggies, has proven very beneficial as it involves the ingestion of the acid form of cannabinoids, which are non-psychoactive (even the THC). Cannabis oil also has enthusiastic fans who claim it has cured their cancers.

 

In India there are still large numbers of people who partake in an ancient practice of having a fresh raw cannabis drink called "Thandai"  in which fresh cannabis leaves are made into a paste along with almonds, milk and sugar. This tasty drink is often consumed at religious festivals, and in some cities the government maintains distribution points for cannabis. A rolled sweet ball with similar ingredients is called "Bhang," familiar for over a century to many Western seekers walking the ghats of sacred Banaras.

 

Cannabis edibles in the West are emerging as one of the fastest growing new sectors of the food industry. Dispensaries in 18 states offer such goodies as ice cream, cough drops, peanut butter, honey, saliva tea, and myriad baked goods and savory snacks--all dosed with THC.  Given the huge potential market for non-psychoactive cannabis, the introduction of CBD-rich medicine at the dispensary level has been surprisingly sluggish. Owners have been reluctant to stock CBD-rich strains or edibles because their present customers are seeking —or are not adverse to— cannabis that provides euphoria or sedation. THC content is a known seller. Once the medical benefits of non-psychoactive cannabis become more widely known, one can only imagine the variety and volume of CBD-rich foods that will rush to market.

 

Smoking, as opposed to vaporization, may be the least effective method of using cannabis as a medicine. But many raw cannabis users are convinced that CBD is the source of medical miracles. Restrictions on research have impacted the accuracy with which we can prescribe cannabis and determine the most effective and least harmful ways to utilize its benefits. Perhaps in the very near future, instead of smoking cannabis to reduce nausea from chemotherapy, cancer patients will be consuming raw non-psychoactive cannabis, and be healed without having to suffer the additional damage of radiation and chemotherapy at all.

 

Pot Treats Cancer Without The Devastating Effects of Chemotherapy

Research shows THC and other compounds found only in marijuana don't just soothe symptoms; they can shrink tumors and slow the spread of cancer. 
By Martin A. Lee

Smoke Signals: A Social History of Marijuana -- Medical, Recreational, and Scientific [2] (Simon and Schuster, 2012):

Peer-reviewed scientific studies in several countries show THC and other compounds found only in marijuana are effective not only for cancer symptom management (pain, nausea, loss of appetite, fatigue, and so on), but they confer a direct antitumoral effect as well.

Animal experiments conducted by Manuel Guzmán at Madrid’s Complutense University in the late 1990s revealed that a synthetic cannabinoid injected directly into a malignant brain tumor could eradicate it. Reported in Nature Medicine, this remarkable finding prompted additional studies in Spain and elsewhere that confirmed the anticancer properties of marijuana-derived compounds. Guzmán’s team administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma (an aggressive form of brain cancer) who had failed to respond to standard therapies. This was the first clinical trial assessing the antitumoral action of cannabinoids on human beings, and the results, published in the British Journal of Cancer, were very promising. THC treatment was associated with significantly reduced tumor cell proliferation in all test subjects.

Guzmán and his colleagues found that THC and its synthetic emulators selectively killed tumor cells while leaving healthy cells unscathed. No Big Pharma chemotherapy drugs could induce apoptosis (cell death) in cancer cells without trashing the whole body. Up to 90 percent of advanced cancer patients suffer cognitive dysfunction from “chemo brain,” a common side effect of corporate cancer meds that indiscriminately destroy brain matter, whereas cannabinoids are free-radical scavengers that protect brain tissue and stimulate brain cell growth.

There is mounting evidence that cannabinoids may “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood vessels] and the metastatic spreading of cancer cells,” according to the scientific journal Mini-Reviews in Medicinal Chemistry. Studies from scientists around the world have documented the anticancer properties of cannabinoid compounds for various malignancies, including (but not limited to):

• Prostate cancer. Researchers at the University of Wisconsin found that the administration of the synthetic cannabinoid WIN-55,212–2, a CB-1and CB-2 agonist, inhibited prostate cancer cell growth and also induced apoptosis.
• Colon cancer. British researchers demonstrated that THC triggers cell death in tumors of the colon, the second leading cause of cancer deaths in the United States.
• Pancreatic cancer. Spanish and French scientists determined that cannabinoids selectively increased apoptosis in pancreatic cell lines and reduced the growth of tumor cells in animals, while ignoring normal cells.
• Breast cancer. Scientists at the Pacific Medical Centers in San Francisco found that THC and other plant cannabinoids inhibited human breast cancer cell proliferation and metastasis and shrank breast cancer tumors. 1.3 million women worldwide are diagnosed yearly with breast cancer and a half million succumb to the disease.
• Cervical cancer. German researchers at the University of Rostock reported that THC and a synthetic cannabinoid suppressed the invasion of human cervical carcinoma into surrounding tissues by stimulating the body’s production of TIMP-1, a substance that helps healthy cells resist cancer.
• Leukemia. Investigators at St. George’s University and Bartholomew’s Hospital in London found that THC acts synergistically with conventional antileukemia therapies to enhance the effectiveness of anti-cancer agents in vitro (in a test tube or petri dish). Scientists had previously shown that THC and cannabidiol were both potent inducers of apoptosis in leukemic cell lines.
• Stomach cancer. According to Korean researchers at the Catholic Uni- versity in Seoul, WIN-55,212–2, the synthetic cannabinoid, reduced the proliferation of stomach cancer cells.
• Skin carcinoma. Spanish researchers noted that the administration of synthetic cannabinoids “induced a considerable growth inhibition of malignant tumors” on the skin of mice.
• Cancer of the bile duct. The administration of THC inhibits bile-duct cancer cell proliferation, migration, and invasion and induces biliary cancer cell apoptosis, according to experiments conducted at Rangsit University in Patum Thani, Thailand.
• Lymphoma, Hodgkin’s and Kaposi’s sarcoma. Researchers at the University of South Florida ascertained that THC thwarts the activation and replication of the gamma herpes virus. This virus increases a person’s chances of developing cancers such as Hodgkin’s, non-Hodgkin’s lymphoma, and Kaposi’s sarcoma.
• Liver cancer. Italian scientists at the University of Palermo found that a synthetic cannabinoid caused programmed cell death in liver cancer.
• Lung cancer. Harvard University scientists reported that THC cuts tumor growth in common lung cancer in half and “significantly reduces the ability of the cancer to spread.” Lung cancer is the number one cancer killer in the world. More Americans die of lung cancer each year than any other type of cancer.

Cannabis oil is a highly efficient natural cancer cure

(NaturalNews) Ever since the mid 70s, medical scientists have been well aware of the beneficial effects of cannabinoid compounds over cancerous cells. Thanks to modern science, over a dozen studies conducted during recent years have been able to partially reveal just how it works. Yet cannabis is still not endorsed by pharmaceutical companies as a cancer cure, and since it is not promoted through mainstream channels, very few people are aware of its benefits. Consequently, it is not sought after as an alternative to disfiguring chemotherapy and other harmful drugs.

Laboratory tests conducted in 2008 by a team of scientists formed as a joint research effort between Spain, France and Italy, and published in The Journal Of Clinical Investigation, showed that the active ingredient in marijuana, known as tetrahydrocannabinol or THC, can function as a cure for brain cancer by inducing human glioma cell death through stimulation of autophagy.

The study concluded that via the same biochemical process THC could terminate multiple types of cancers, affecting various cells in the body. Other studies have shown that cannabinoids may work by various mechanisms, including inhibiting cell growth, inducing cell death, and inhibiting tumor metastasis.

What is amazing is that while cannabinoids effectively target and kill cancerous cells, they do not affect healthy, normal cells and may actually protect them against cellular death. Moreover, cannabinoids are also researched for their pain-modulation and anti-inflammatory abilities as they bind to special receptors in the brain, much like opioid derivatives that are commonly prescribed today.

Further evidence to support the effects of cannabis extract on malignant cells comes from the real life experience of individuals who have successfully overcome cancer by using cannabis oil. Examples include a patient, who managed to completely cure his skin cancer by simply applying cannabis oil onto the affected areas of the skin, as well as another, who recovered from a severe head injury with the aid of hemp oil.

One of the cannabinoids that has displayed amazing medical properties is cannabidiol, or CBD - a non-psychoactive compound that is regarded by some as the medical discovery of the 21st century, and with good reason. Research indicates that CBD can relieve convulsions, reduce inflammation, lower anxiety and suppress nausea, while also inhibiting cancer development. In addition, CBD has exhibited neuroprotective properties, relieving symptoms of dystonia and proving just as effective as regular antipsychotics in the treatment of schizophrenia.

What stands out is that from the vast amount of research and data available, as well as the personal experiences of cancer survivors, is that no chemotherapy currently being used medically can match the non-toxic anti-carcinogenic and anti-tumorigenic effects of these natural plant compounds.

Sources for this article include:

http://safeaccess.ca/research/cancer.htm
http://www.jci.org/articles/view/37948
http://dotsub.com/media/fc4e051a-1709-4e63-8a2c-912b09486c9f/e/m
http://en.wikipedia.org/wiki/Cannabidiol

Merck Pays a Pittance for Mass Deaths

 (Maybe the biggest corporate/political lie out there is that pharmaceutical companies are these hard working scientists toiling to find a cure for every ailment known to man. People believe pharma is here for us, to make us better when we get sick.  They are sanctioned drug dealers who can get away with anything they want because they have billions of dollars to throw at any problem that could arise, any politicians who can be bought for the right price, and any pusillanimous, pretend regulatory agency like the impotent FDA, manned by future employees of big pharma once they leave "public service." 

The biggest joke is on sick people who desperately need something to feel better, to heal, and they have no choice (it seems to them) but to put all their faith in big pharma's latest, newest drug trial. When people stopped taking the anti-psychotic Orap (Pimozide) due to its horrible side effects, its makers had it reclassified as an anti-depressant so that they could milk it for more profits. The side effects of it range from akathisia (inability to sit still or stay in one place), tardive dyskinesia (repetitive, uncontrollable body movements) , and,possibly, neuroleptic malignant syndrome to death. They prescribe it to people with delusions, too. 

The drug companies exist to make huge mountains of profits. There's no money in curing any disease because diseases are huge money makers, especially cancer. A drug company, hospital and insurance company can milk hundreds of thousands of dollars out of one cancer patient. Oh, and these guys are very generous donors to political campaigns...no one can offer as much money to a campaign except for the banks.

And finally my point: so is it any wonder at all to any reasonably thinking human being that Merck would actually be punished? No one goes to jail, no one loses their job--even though there were numerous deaths--maybe conspiracy to commit murder, or voluntary manslaughter. And we keep taking each and every new pill they shit down the pike... and that fine amounts to nothing t=for a company that routinely clears billions of dollars per year net profit.

"This one will work! Oh,no! Maybe this one? Ahhhhh nooo, well something's gotta work! how about this one? Ooooohhhh..." And it's obvious that they only make things worse. --jef)

The VIOXX Settlement

by FRED GARDNER

Q: Who killed more Americans —al Qaeda crashing airplanes into the World Trade Center, or Merck pushing Vioxx?
A: Merck, by a factor of 18.

One of the most downplayed stories of our time ended with a whimper this week.  “Merck has agreed to pay $950 million and has pleaded guilty to a criminal charge over the marketing and sales of the painkiller Vioxx,” the New York Times reported Nov. 23 (in the business section, where important medical news is usually found).  The pharmaceutical giant copped to a misdemeanor: urging MDs to prescribe Vioxx for Rheumatoid Arthritis prior to 2002, when the Food & Drug Administration approved its use for that disorder.

The FDA had initially approved Vioxx (after a hasty “priority review”) in May, 1999 to treat osteoarthritis, acute pain, and menstrual cramps.  By September 30, 2004, when Merck announced its “voluntary recall,” some 25 million Americans had been prescribed the widely hyped drug. Evidence that using Vioxx doubled a patient’s risk of suffering a heart attack or stroke —based on a review of 1.4 million patients’ records— was about to be published in Lancet by David Graham, MD, an FDA investigator.  The FDA director’s office, devoted valet of Big PhRMA, had contacted the Lancet in a futile effort to stop publication of their own scientist’s findings.

Graham’s data indicate that 140,000 Americans suffered Vioxx-induced heart attacks and strokes; 55,000 died, and many more were permanently disabled. The Merck executives’ real crime was conspiracy to commit murder.

Some 3,000 Americans died in the attack on the World Trade Center. The murders perpetrated by Merck executives were not as dramatic, obviously, but were every bit as intentional. An early clinical trial had alerted them to the fact that Vioxx caused coronary damage. Their response was to exclude from future trials anyone with a history of heart trouble!

Once Vioxx was approved, Merck spent more than $100 million a year advertising it.  (You may still remember the tune to “It’s a beautiful morning…”) Merck execs continued to ignore and suppress indications that their new blockbuster was causing strokes and heart attacks.

Sales hit $2.5 billion in 2003. And when brave Dr. Graham first presented his irrefragable evidence to an FDA advisory committee in February 2004, Merck argued that the “unique benefits” of Vioxx warranted its remaining on the market. The FDA committee voted 17-15 to keep it available with a black box warning. Ten of the 32 committee members had taken money from Merck, Pfizer or Novartis (which were pushing drugs similar to Vioxx) as consultants.  If these MDs had declared their conflicts of interest, Vioxx would have been pulled from the market by a vote of 14-8. By buying an extra seven and a half months, Merck made an extra billion or two, and killed 6,000 more Americans.

Worldwide, Vioxx was used by 80 million people. Assuming their dosages were similar to the 1.4 million Kaiser Permanente patients whose records Dr. Graham analyzed, the death toll exceeds 420,000.

The great selling point to doctors —and the original rationale for developing “Cox-2 inhibitors” such as Vioxx and Celebrex— was their supposed safety compared to aspirin and other non-steroidal anti-inflammatories such as ibuprofen (Motrin, Advil) and naproxen (Aleve), which can cause gastrointestinal bleeding and peptic ulcers in some people. (There was no evidence that Cox-2 inhibitors were more effective than NSAIDs at reducing pain and inflammation.)

The NSAIDs work by inhibiting production of an enzyme, Cyclooxygenase, that helps make compounds called prostaglandins that facilitate the inflammatory response and protect the stomach lining (among other functions).  In the 1980s a researcher named Philip Needleman discovered that the body makes Cyclooxygenase in two forms —Cox-1, found in normal tissue, and Cox-2, which is more prevalent in damaged tissues associated with arthritis. The drug companies hoped that a compound that inhibited only Cox-2 production would reduce inflammation without gastric side effects. With 40 million Americans suffering from some form of Arthritis, an easier-on-the-stomach painkiller would mean blockbuster sales. And so they invested hundreds of millions of dollars in the ’90s developing compounds that would inhibit Cox-2 production, and arranging clinical trials to convince the FDA that such drugs were an improvement over the existing alternatives.

And now a word from our sponsor
If Cannabis and Cannabis-based medicines had been among the alternatives, the market for Vioxx et al would have been much smaller. (And if codeine wasn’t semi-prohibited, the market would have been smaller still.) How many drugs would lose significant market share if Cannabis-based options were available? Enough so that the pharmaceutical industry would quickly follow the housing sector down the drain.  Which is why Wall Street cannot allow legalization of the plant for medical use.

It may turn out that a cannabinoid produced by the plant, cannabidiol (CBD), exerts its anti-inflammatory effects by means of Cox-2 inhibition. A recent study shows that Cox-2 plays a role in breaking down one of the cannabinoids produced by the body, 2-AG. The breakdown product is a precursor to neuroinflammatory prostaglandins.

Let the punishment fit the crime
In 2007 Merck paid out $4.85 billion to settle claims by 27,000 Vioxx victims and their survivors. “The reason ‘so few’ people filed lawsuits,” a physician explains, “is that there is a significant background rate of heart attack. People may not have recognized their event as being related to Vioxx.”  The survivors of people who smoked cigarettes, were overweight or had other risk factors would have been discouraged by lawyers from filing claims, he added, because they’d have a hard time convincing jurors that their loved ones’ heart attacks were brought on by Vioxx use.

“No person was held liable for Merck’s conduct,” Duff Wilson of the Times reported Nov. 23.

To be fair-and-balanced in an otherwise Merck-friendly story, he quoted Erik Gordon of the University of Michigan’s Ross School of Business, commenting “It’s just a cost of doing business until a pharmaceutical executive does a perp walk.”

That sounds tough but it isn’t.  Marketing dangerous drugs would still be “just a cost of doing business” to profit-driven corporations if a few individual execs were made to do time at Camp Fed. Why shouldn’t they be charged with conspiracy to commit murder, along with every accessory to the crime that a thorough investigation could identify? (This could provide meaningful work for the currently useless Drug Enforcement Administration.) The Vioxx conspiracy involved researchers who skewed data and sales execs who framed false pitches and government officials who tried to silence whistleblowers and God knows who else… If somebody is killed in a botched robbery at a Seven Eleven, the kid driving the getaway car is charged with homicide. But Merck’s CEO throughout the Vioxx era, Ray Gilmartin, left the company in 2006 with a golden parachute and joined the Harvard Business School faculty. The class he teaches is called “Building and Sustaining Successful Enterprises.”

A more effective way to counter deadly corporate fraud would be for the government to simply stop doing business with entities convicted of major crimes. If MediCare and state Medicaid programs stopped buying Merck or Pfizer drugs for, say, five years, it just might produce the result that we, the people, require.

The day before the Vioxx settlement was reported, the Wall St. Journal ran a story (in the Marketplace section) under the headline “Pfizer Near Settlement on Bribery.”  The corporate boo-boo in this instance involved pay-offs to doctors who purchase drugs for state-owned institutions overseas. Johnson & Johnson recently settled a similar bribery case. Merck, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline are all in settlement negotiations with the government.

On the home front, Pfizer has paid $2.3 billion for violating the federal False Claims Act and bribing institutional purchasers in connection with Bextra, Lipitor, Viagra, Zithromax, Norvasc, Lyrica, Relpax, Celebrex, and Depo-provera.

The systemic corruption is getting worse.  In the 15 years between 1991 and 2005, according to Public Citizen, drug companies paid the government $5 billion in penalties and settlements in connection with kickbacks and false claims. In the five years between 2006 and 2010 the pay out was $14.8 billion.  Four companies accounted for more than half the blood money ($10.3 billion): Glaxo, Pfizer, Eli Lilly, and Schering-Plough.

In recent years the drug industry has surpassed the “defense” industry as the top defrauder of the federal government under the False Claims Act.

Where is zero tolerance when we need it?

The Wonder Drug of the 21st Century?

Cannabidiol
Schaffer Library of Drug Policy

The traditional use of Cannabis as an analgesic, anti-asthmatic, and anti-rheumatic drug is well established. This British study also suggests that cultivation of Cannabis plants rich in Cannabidiol (CBD) and other phenolic substances would be useful not only as fiber producing plants but also for medicinal purposes in the treatment of certain inflammatory disorders. CBD was found to be more effective than aspirin as an anti-inflammatory agent. "Analgesic and Anti-inflammatory Activity of Constituents of Cannabis Sativa L.," E.A. Formukong, A.T. Evans, and F.J. Evans, Inflammation, Vol. 4, 1988, pp. 361-371.

Cannabidiol, CBD, a non-psychoactive cannabinoid of Marijuana, was given to 5 patients with dystonia disorders. Improvement occurred in all 5 patients by 20-50%. "Open Label Evaluation of Cannabidiol in Dystonic Movement Disorders," Consroe, et al, International Journal of Neuroscience, 1986, Vol. 30, pp.277-282.

Three patients with Huntington's Disease who had been previously unresponsive to therapy with neuroleptics, were given Cannabidiol, (CBD), a non-psychoactive cannabinoid of Marijuana. After the second week improvement in choreic movement occurred by 20-40%. Except for transient, mild hypo-tension no side effects were recorded."Effects of Cannabidiol in Huntington's Disease," Sandyk, Consroe, Stern, and Snider, Neurology, 36 (Suppl. 1) April, 1986, p.342.

In this Brazilian study of 8 Epileptic patients receiving Cannabidiol, (CBD), 4 were free of convulsions, 3 had partial improvement, and 1 was unchanged. No serious side effects were found. This is quite important, as complex partial seizures with secondary generalization are difficult to treat with currently used drugs. The potential use of CBD as an anti-epileptic drug and its possible potentiating effect on other drugs are discussed. "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients," Pharmacology, 21: 1980, J.M. Cunha, et al, pp.175-185.

Subjects receiving 160 mg. Cannabidiol reported having slept significantly more than those receiving placebo; seven out of eight epileptics receiving Cannabidiol had improvement of their disease state. (Brazil) "Hypnotic and Antiepileptic Effects of Cannabidiol," Carlini, E.A., and Cunha, J.A., Journal of Clinical Pharmacology 1981: 21: pp. 417S-427S.

Three patients with TS who experienced incomplete responses to conventional anti-TS drugs but noted a significant amelioration of symptoms when smoking marijuana. The effects of marijuana on TS may be related to its anxiety-reducing properties, although a more specific antidyskinetic effect cannot be excluded. Eliminating the psychoactive properties of marijuana while retaining the antidyskinetic effects (Cannabidiol) could prove beneficial. "Marijuana and Tourette's Syndrome," (letter), Sandyk and Awerbuch, Journal of Clinical Psychopharmacology, Vol. 8, No. 6, Dec. 1988, pp.444-5.

"Anti-dyskinetic effects of cannabidiol," Conti, L.H., Johannesen, J., Musty, R.E., Consroe, P., Proceedings of the International Congress on Marijuana. 1987: 21. Melbourne, Australia.

This Brazilian study Investigates the possible anti-psychotic activity of CBD by studying the effect of this cannabinoid on animal models used in research with potential anti-psychotic properties. CBD seems to compare favorably with haloperidol as an anti-psychotic. "Effects of CBD in animal models predictive of anti-psychotic activity," Zuardi, A.W., Rodrigues, J.A., Cunha, J.M., Psychopharmacology 1991: 104: pp. 260-264.

CBD blocks some of the effects of THC in mice but potentiates some other effects. (Brazil)"Pharmacological Interaction between Cannabidiol and Tetrahydrocannabinol," Karniol, I.G., Carlini, E.A., Psychopharmacologia 1973: 33: pp. 53-70.

CBD was effective in blocking most of the effects of THC, increased pulse rate, disturbed time tasks, and psychological reactions. CBD also decreased the anxiety components of THC. (Brazil) "Cannabidiol Interferes with the effects of Tetrahydrocannabinol in Man," Karniol, I.G., Shirakawa, I., Kasinski, N., Pfeferman, A., Carlini, E.A., European Journal of Pharmacology 1974: 28: pp. 172-177.

One of the first studies that clearly shows that hemp grown for fiber is very low in THC, the psychoactive component that gets people high. The drug-type marijuana is very high in THC. Cannabidiol (CBD) which is not psychoactive, is very high in fiber-type hemp but low in drug-type marijuana. This is important as CBD is known to block the effects of THC.

This makes the hemp doubly useless for drug effects. "Chemistry of Marijuana," Coy Waller. Pharmacological Reviews, Vol. 23, No. 4, 1971.

Wild 'marijuana' growing in Riley County Kansas was found to be very low in THC content. (Below the European threshold for fiber hemp.) The leaves and flowering tops averaged from 0.01-0.49% THC with a mean of 0.14% THC. CBD which blocks the psychoactive effects of THC was as high as 1.7%. "Seasonal Fluctuations in Cannabinoid Content of Kansas Marijuana," R.P. Latta, and B.J. Eaton. Economic Botany, 29: April-June, 1975, pp. 153-163.

Researchers for the Canadian Department of Agriculture tested over 350 varieties of Cannabis in Ottawa, Ontario. They determined that there were two basic types of Cannabis based on genetic characteristics: a drug-type which originates in hot climates such as India and is high in THC but low in CBD and a fiber-type which originates in temperate climates and is low in THC but high in CBD and is used industrially for fiber and food. This awareness of the separateness of the two phenotypes has vast agronomic potential. It means fiber hemp can be grown without the drug effect of 'marijuana.'"The Evolution of Cannabinoid Phenotypes in Cannabis," Ernest Small, H.D. Beckstead, and Allan Chan, Economic Botany, 29: 1975, pp. 219-232.

Ten mg. of THC is required to get a psychoactive effect from 'marijuana.' It would require 50-100 cigarettes of the French hemp cultivated for paper to get a psychoactive high. "Paper-making type of hemp (Cannabis sativa L.) cultivated in France: Constituents compared to those of marijuana," Fournier and Paris, (French) Plantes Medicinales et Phytotherapie, Vol. 13(2) April, 1979, pp. 116-121.

++++++

What is Cannabidiol?

Cannabidiol, also known as CBD, is a cannabinoid found in Cannabis. It is a major constituent of the plant, representing up to 40% in its extracts.
CBD alone is not intoxicating, but displayed sedative effects in animal tests. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. CBD does not appear to affect either the CB₁ or CB₂ receptors. Some research, however, indicates that CBD can increase alertness.
Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea, and to inhibit cancer cell growth. Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia. In November 2007 it was reported that CBD reduces growth of aggressive human breast cancer cells in vitro and reduces their invasiveness. It thus represents the first non-toxic exogenous agent that can lead to down-regulation of tumor aggressiveness. It is also a neuroprotectiveantioxidant.
(Wikipedia)

Marijuana Facts and Resources:

• Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity
  “This study provides the first demonstration of CBD as an in vivo neuroprotectant and shows the efficacy of lipophilic antioxidants in preventing binge ethanol-induced brain injury.”
  
• Cannabinol delays symptom onset
  “We found that this treatment significantly delays disease onset by more than two weeks while survival was not affected.”
• Cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
  “In the present study, we report that CBD has a beneficial therapeutic action on established CIA, and we explore its mode of action.”
• Cannabidiol inhibits tumour growth in leukaemia and breast cancer
  “These observations are supported by investigations of US scientists who found out that exposure of leukaemia cells to CBD led to a reduction in cell viability and induction of apoptosis. In living animals CBD caused a reduction in number of leukaemia cells. The scientists noted that CBD “may be a novel and highly selective treatment for leukemia.”
• Anti-tumor effects of cannabidiol
  “Concluding, the non-psychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent.”
• Cannabidiol triggers caspase activation and oxidative stress in human glioma cells.
  “Thus, we found a different sensitivity to the anti-proliferative effect of CBD in human glioma cells and non-transformed cells that appears closely related to a selective ability of CBD in inducing ROS production and caspase activation in tumor cells.”
• Cannabidiol-Induced Apoptosis in Human Leukemia Cells
  “Together, the results from this study reveal that cannabidiol, acting through CB2 and regulation of Nox4 and p22^phox expression, may be a novel and highly selective treatment for leukemia.”
• Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
  “Our results indicate that CBD can inhibit and delay destructive insulitis and inflammatory Th1-associated cytokine production in NOD mice resulting in a decreased incidence of diabetes possibly through an immunomodulatory mechanism shifting the immune response from Th1 to Th2 dominance.”
• Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol
  “These results demonstrate that CBD treatment reduces neurotoxicity, inflammation, and BRB breakdown in diabetic animals through activities that may involve inhibition of p38 MAP kinase.”
• Evaluation of cannabidiol in dystonic movement disorders
  “20-50% improvement of dystonia; deterioration of tremor and hypokinesia in 2 patients with Parkinson’s disease”
• Cannabidiol in dystonic movement disorders.
  “Cannabidiol (CBD) reduced dystonic movements”
• Beneficial and adverse effects of cannabidiol in a Parkinson patient
  Study showing an improvement of dyskinesia
• Treatment of Meige’s syndrome with cannabidiol.
  “50% improvement in spasm severity and frequency”
• Cannabidiol to Healthy Volunteers and Epileptic Patients
  “The clinical condition of 7 placebo patients remained unchanged whereas the condition of 1 patient clearly improved. The potential use of CBD as an antiepileptic drug and its possible potentiating effect on other antiepileptic drugs are discussed.”
• Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
  “4 of the 8 CBD subjects remained almost free of convulsive crises and 3 other patients demonstrated partial improvement”
• Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol
  “The neuroprotection by THC and CBD was because of attenuation of peroxynitrite. The effect of THC was in part mediated by the cannabinoid receptor CB1. These results suggest the potential use of CBD as a novel topical therapy for the treatment of glaucoma.”
• Effects of Cannabidiol in Huntington’s Disease
  “The patients;, aged 30 to 56, had HD of 7 to 12 years’ duration. Their condition has been slowly progressive and unresponsive to prior therapy with neuroleptics. Orally administered CBD was initiated at 300 mg/d and increased 1 week later to 600 mg/d for the next 3 weeks. Mild improvement ( 5 to 15%) in the choreic movements was documented using the tongueprotrusion test…”
• Cannabidiol has a cerebroprotective action
  “Cannbidiol provides potent and long-lasting neuroprotection through an anti-inflammatory CB(1) receptor-independent mechanism, suggesting that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.”
• Cannabidiol as an antipsychotic
  “CBD was as effective as amisulpride, a standard antipsychotic”
• Cannabidiol May be Effective in Preventing Bovine Spongiforme Enzephalopathy (Mad Cow Disease)
  “According to basic research of scientists of the National Centre for Scientific Research in Valbonne, France, cannabidiol (CBD) may prevent the development of prion diseases, the most known being BSE (bovine spongiforme enzephalopathy), which is often called mad cow disease.”
• Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.
  “Cannabidiol selectively reduces croton oil-induced hypermotility in mice in vivo and this effect involves cannabinoid CB(1) receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease.”
• Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
  “The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.”
• Composition of the essential oils and extracts of two populations of Cannabis sativa L. ssp. spontanea from Austria
  “The essential oil and the solvent extract of two populations of Cannabis sativa L. ssp. spontanea growing wild in Austria were analyzed comparatively.”
• Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs. amisulpride in acute schizophrenia.
  “Cannabidiol significantly reduced psychopathological symptoms of acute psychosis.”
• Treatment with CBD in oily solution of drug-resistant paediatric epilepsies.
  “Improvement of epilepsy without side effects”
• Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats.
  “These results indicate that CBD may be useful to control bone resorption during progression of experimental periodontitis in rats.”
• The nonpsychoactive cannabis constituent cannabidiol is a wake-inducing agent.
  “These findings suggest that this cannabinoid is a wake-inducing compound that presumably activates neurons in LH and DRN.”

The following links require you to login. Registration is free, however you can use the following credentials to login:

Username: showmethefacts
Password: smtfplease

• The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
• Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.

Anecdotal:

• Who’s Afriad of Cannabidiol?
  “THC -delta-9 tetrahydrocannabinol is often described inaccurately as “the active ingredient in cannabis.” At least five other cannabinoids (compounds unique to the cannabis plant) have been shown to exhibit biological activity, and so have some of the spicy-smelling terpenes and other compounds found in plants other than cannabis.”

How Cannabis Works

"What is the end of our revolution? The tranquil enjoyment of liberty and equality; the reign of that eternal justice, the laws of which are graven, not on marble or stone, but in the hearts of men, even in the heart of the slave who has forgotten them, and in that of the tyrant who disowns them."

-- Maximillien Robespierre

Wake Up and Smell the Terpenes!
By FRED GARDNER

The chemical structure of tetrahydrocannabinol (THC) was determined in 1964 by Raphael Mechoulam and Yechiel Gaoni. For more than three decades thereafter, its blatant psychoactivity induced scientists to define THC as the active ingredient in the plant.

Experienced marijuana smokers who tried the drug Marinol (pure, synthetic THC) when it became prescribable in the mid-1980s, reported that the effects were noticeably dissimilar. But it wasn’t until the late 1990s that the research establishment acknowledged that another compound, cannabidiol (CBD), was exerting significant effects, too. 

In 1999 a British start-up, G.W. Pharmaceuticals, began clinical trials of a plant extract containing equal amounts of THC and CBD. Multiple Sclerosis patients found the combination more effective in reducing pain and spasticity than a THC extract, and less psychoactive. The THC-CBD combo, “Sativex,” has now been approved for use by MS patients in England, Canada, New Zealand, and a growing list of European countries. 

Several of the so-called “minor cannabinoids” —notably tetrahydrocannabavarin (THCV), cannabigerol (CBG) and cannabichromene (CBC)— also show therapeutic promise, and plants with high levels of each have been grown out in G.W.’s glasshouses for research purposes.

Now scientists are formally acknowledging something else that Cannabis consumers have long taken for granted: aroma is associated with effect.

Plant cannabinoids —21-carbon molecules found only in Cannabis— are odorless. It’s the terpenoids —components of the plant’s “essential oils”— that create the fragrance. Terpenoids contain repeating units of a 5-carbon molecule called isoprene, and are prevalent in smelly herbs such as mints and sage, citrus peel, some flowers, aromatic barks and woods. The aroma of a given plant depends on which terpenoids predominate. They tend to be volatile molecules that readily evaporate, and they’re very potent —all it takes is a few reaching the nose to announce their presence. The cannabinoid content of a trichome might be 10 times heavier than the terpenoid content. 

Evidence that “phytocannabinoid-terpenoid interactions” enhance the therapeutic effects of cannabis was presented by Ethan Russo, MD, at a conference in Israel last fall and is about to be published in the British Journal of Pharmacology. Russo, a neurologist and ethnobotanist,, is senior medical adviser at G.W. Pharmaceuticals.

Terpenoids and cannabinoids are both secreted inside the Cannabis plant’s glandular trichomes and they have a parent compound in common (geranyl pyrophosphate). More than 100 terpenoids have been identified in Cannabis. The most common and most studied include limonene, myrcene, alpha-pinene, linalool, beta-caryophyllene, caryophyllene oxide, nerolidol and phytol. Anecdotal evidence suggests that alpha-pinene is alerting, limonene is “sunshine-y,” and beta-myrcene is sedating.

 As the names suggest, pinene is abundant in pine needles and limonene in lemons. Myrcene is found in hops (Humulus), the only other member of the Cannabicae plant family.

The fact that most terpenoid compounds are common components of the human diet and “generally recognized as safe” by the Food and Drug Administration has made research possible, and scientists employed by flavors and fragrances manufacturers have investigated their properties over the years. But the terpenoids “remain understudied” in terms of therapeutic potential, according to Russo. 

His paper mustered all the evidence —proof in some cases, mere hints in others—  that cannabinoid-terpenoid synergy is involved when Cannabis abates the symptoms of various conditions. He listed “pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus).”

For example, as an indication that some terpenoids may, like CBD, be “antidotes to the intoxicating effects of THC,” Russo noted that traditional responses to Cannabis overdose include limonene-rich citrus and pinene-rich black pepper.

Jeffrey Hergenrather, MD, president of the Society of Cannabis Clinicians, who attended Russo’s talk in Israel, expects its publication to “generate great interest in terpenes among medical cannabis users as well as physicians.” The SCC recently began collecting data on patients’ responses to CBD-rich Cannabis. Future surveys will seek to document which terpenoids are having which effects.

The “Entourage Effect”

The conference at which Russo presented his paper was held at Hebrew University, Jerusalem, where Raphael Mechoulam directs a lab, in honor of Mechoulam’s 80th birthday.  

In 1999 Mechoulam co-authored a paper with Shimon Ben-Shabat suggesting that cannabinoids made in the body work by means of an “entourage effect.” They had found that the endocannabinoid 2-AG (2-arachidonoylglycerol), tested by itself, did not bind very strongly to the cannabinoid receptors or exert pronounced behavioral effect on mice. But when administered with two related compounds, it did both. 

To pharmacologists who customarily designed experiments aimed at finding the active ingredient, this had heavy implications. Mechoulam spelled them out: “Biochemically active natural products, from either plant or animal origin, are in many instances accompanied by chemically related though biologically inactive constituents. Very seldom is the biological activity of the active constituent assayed together with inactive ‘entourage’ compounds. 

Investigations of the effect of the active component in the presence of its ‘entourage’ compounds may lead to results that differ from those observed with the active component only.”

In 2001 John McPartland and Russo published a paper in the Journal of Cannabis Therapeutics applying the “entourage” concept to the plant itself.  “Good evidence shows that secondary compounds in cannabis may enhance the beneficial effects of THC... and reduce THC-induced anxiety, cholinergic deficits, and immunosuppresion,” they wrote. “Cannabis terpenoids and flavonoids may also increase cerebral blood flow, enhance cortical activity, kill respiratory pathogens, and provide anti-inflammatory activity.” 

A decade later, Russo is substantiating the molecular-teamwork hypothesis and expanding on it. His forthcoming BJP paper, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” contains 304 citations.

A really good scientific review paper is built like a stone wall by an artistic mason. Documented fact upon documented fact upon documented fact, with insights positioned fittingly. Russo, citing Robert Clarke (2010), suggests that “distinctions between available cannabis ‘strains’ are most likely related to relative terpenoid contents and ratios.” Citing David Potter (2009), he notes that “the mechanical stickiness of the trichomes [is] capable of trapping insects with all six leg.”  Citing Jirovetz et al, “Linalool is the likely suspect in the remarkable therapeutic capabilities of lavender essential oil to alleviate skin burns without scarring.”  

Citing investigators too numerous to list here, Russo reports the effects attributed to various terpenoids:

• Limonene (also found in lemon): Potent immunostimulant via inhalation. Anxiolytic. Apoptosis of breast cancer cells. Active agent against acne bacteria. Dermatophytes. Gastro-esophaeal reflux. 
• Alpha-pinene (found in pine needles): Bronchodilatory in humans. Acetylcholinesterase inhibitor, aiding memory.
• Beta-myrcene (found in hops): Blocks inflammation via PGE-2. Analgesic, antagonized by naloxone. Sedating, muscle relaxant, hypnotic. Blocks hepatic carcinogenesis by aflatoxin.
• Linalool (found in lavender): Anti-anxiety. Sedative on inhalation in mice. Local anesthetic. Anagesic via adenosine A2A. Anticonvulsant/anti-glutamate.
• Beta-Caryophyllene (found in pepper, Echinacea): Potent anti-leishmanial. Gastric cytoprotective. Anti-malarial. Selective CB2 antagonist. Treatment of pruritis? Treatment of addiction? Decreases platelet aggregation. 
• Caryophyllene Oxide (found in lemon balm): Anti-fungal. Insecticidal. 
• Nerolidol (found in orange): Sedative. Skin penetrant. Potent antimalarial. Anti-leishmanial activity. Breakdown product of chlorophyll. 
• Phytol (found in green tea): Prevents Vitamin-A teratogenesis. Increases GABA.
  

Cannabinoids Formerly Known as Minor

Although this article has focused on the terpenoids, Russo’s talk in Israel gave equal time to CBD, THC-V, CBC, and CBG (the parent compound of the others). Evidently the extensive breeding program directed by G.W.’s Etienne de Meijer has yielded plants rich in each of these cannabinoids, and probably others. At the 2011 meeting of the International Cannabinoid Research Society, held in Chicago in July, several talks and posters described promising results with G.W. extracts whose exact contents were not revealed by the investigators. 

Intrepid California cultivators are trying to follow G.W.’s lead. Labs have already begun testing for the cannabinoids that may not be “minor” after all, and for terpenoids.  

Projectcbd.org will help collect and report on patients’ responses to the newly identified active ingredients. Maybe we should have called it BeyondTHC.com… The “entourage effect” applies to politics, too. The drug policy reform movement, like all single-issue movements, is the political equivalent of Marinol... More on all this in O’Shaughnessy’s, due out next month. To order or place an ad (enabling us to pay the printer), contact the managing editor (me), fred@plebesite.com.